专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09511151B2 Compositions and methods for the prevention and treatment of cancer 有权
标题翻译：预防和治疗癌症的组成和方法
公开(公告)号：US09511151B2
公开(公告)日：2016-12-06
申请号：US13294109
申请日：2011-11-10
申请人： Pedro Santamaria
发明人： Pedro Santamaria
IPC分类号： A61K39/00 , A61K39/38 , A61K45/00 , A61K47/48
CPC分类号： A61K47/48861 , A61K47/48238 , A61K47/48884 , A61K47/62 , A61K47/6923 , A61K47/6929
摘要： Conventional cancer immunotherapy falls short at efficiently expanding T cells that specifically target cancerous cells in numbers sufficient to significantly reduce the tumor size or cancerous cell number in vivo. To overcome this limitation, provided herein are nanoparticles coated with MHC class I and/or class II molecules presenting tumor-specific antigens and co-stimulatory molecules and their use to expand antigen-specific anti-tumorigenic T cells to levels not achieved in current immunotherapeutic techniques. These antigen-specific anti-tumorigenic T cells include cytotoxic T cells, effector T cells, memory T cells, and helper T cells that are necessary to initiate and maintain a substantial immune response against metastatic or non-metastatic cancerous, pre-cancerous, or neoplastic cells in vivo. The present invention describes a systemic approach to targeting cancerous or pre-cancerous cells that are circulating cells, as in lymphomas, migratory metastatic cells, and solid tumors.
摘要翻译：常规的癌症免疫治疗缺乏有效扩张的特异性靶向癌细胞的T细胞，其数量足以显着降低体内肿瘤大小或癌细胞数量。为了克服这个限制，本文提供的纳米颗粒涂覆有呈现肿瘤特异性抗原和共刺激分子的MHC I类和/或II类分子，以及它们将抗原特异性抗致瘤性T细胞扩增至目前免疫治疗未达到的水平技术这些抗原特异性抗致瘤性T细胞包括细胞毒性T细胞，效应T细胞，记忆T细胞和辅助T细胞，其是启动和维持针对转移性或非转移性癌，癌前或非转移性癌症的实质性免疫应答所必需的体内肿瘤细胞。本发明描述了靶向作为淋巴瘤，迁移性转移细胞和实体瘤中循环细胞的癌性或癌前细胞的系统方法。

2. 发明申请

US20090155292A1 COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE CONDITIONS 有权
标题翻译：防止和治疗自身免疫条件的组合物和方法
公开(公告)号：US20090155292A1
公开(公告)日：2009-06-18
申请号：US12044435
申请日：2008-03-07
申请人： Pedro SANTAMARIA , Anna MOORE
发明人： Pedro SANTAMARIA , Anna MOORE
IPC分类号： A61K39/39 , C12Q1/68 , G01N33/566 , A61P3/10
CPC分类号： A61K39/0008 , A61K9/5094 , A61K39/385 , A61K47/6923 , A61K47/6929 , A61K2039/55555 , A61K2039/572 , A61K2039/60 , A61K2039/605 , A61K2039/6093 , A61K2039/627 , G01N33/54313 , G01N33/564 , G01N33/56972 , G01N2333/70539 , G01N2800/042
摘要： The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases.
摘要翻译：所述方法包括根据T细胞的抗原特异性选择性地还原或扩增T细胞。因此，本发明可用于减少或消除识别自身抗原的致病性T细胞，例如β细胞特异性T细胞。因此，本发明可用于预防，治疗或改善自身免疫性疾病如IDDM。此外，本发明可用于扩展期望的T细胞，例如抗致病性T细胞，以预防，治疗和/或改善自身免疫性疾病。

3. 发明授权

US08354110B2 Compositions and methods for the prevention and treatment of autoimmune conditions 有权
标题翻译：用于预防和治疗自身免疫病症的组合物和方法
公开(公告)号：US08354110B2
公开(公告)日：2013-01-15
申请号：US12044435
申请日：2008-03-07
申请人： Pedro Santamaria , Anna Moore
发明人： Pedro Santamaria , Anna Moore
IPC分类号： A61K39/00 , A61K39/38 , A01N25/26 , A01N25/28
CPC分类号： A61K39/0008 , A61K9/5094 , A61K39/385 , A61K47/6923 , A61K47/6929 , A61K2039/55555 , A61K2039/572 , A61K2039/60 , A61K2039/605 , A61K2039/6093 , A61K2039/627 , G01N33/54313 , G01N33/564 , G01N33/56972 , G01N2333/70539 , G01N2800/042
摘要： The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases.
摘要翻译：所述方法包括根据T细胞的抗原特异性选择性地还原或扩增T细胞。因此，本发明可用于减少或消除识别自身抗原的致病性T细胞，例如β细胞特异性T细胞。因此，本发明可用于预防，治疗或改善自身免疫性疾病如IDDM。此外，本发明可用于扩展期望的T细胞，例如抗致病性T细胞，以预防，治疗和/或改善自身免疫性疾病。

4. 发明申请

US20120121649A1 COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER 有权
标题翻译：预防和治疗癌症的组合物和方法
公开(公告)号：US20120121649A1
公开(公告)日：2012-05-17
申请号：US13294109
申请日：2011-11-10
申请人： Pedro Santamaria
发明人： Pedro Santamaria
IPC分类号： A61K39/00 , C07K17/00 , A61P35/00 , A61P37/04 , B82Y5/00
CPC分类号： A61K47/48861 , A61K47/48238 , A61K47/48884 , A61K47/62 , A61K47/6923 , A61K47/6929
摘要： Conventional cancer immunotherapy falls short at efficiently expanding T cells that specifically target cancerous cells in numbers sufficient to significantly reduce the tumor size or cancerous cell number in vivo. To overcome this limitation, provided herein are nanoparticles coated with MHC class I and/or class II molecules presenting tumor-specific antigens and co-stimulatory molecules and their use to expand antigen-specific anti-tumorigenic T cells to levels not achieved in current immunotherapeutic techniques. These antigen-specific anti-tumorigenic T cells include cytotoxic T cells, effector T cells, memory T cells, and helper T cells that are necessary to initiate and maintain a substantial immune response against metastatic or non-metastatic cancerous, pre-cancerous, or neoplastic cells in vivo. The present invention describes a systemic approach to targeting cancerous or pre-cancerous cells that are circulating cells, as in lymphomas, migratory metastatic cells, and solid tumors.
摘要翻译：常规的癌症免疫治疗缺乏有效扩张的特异性靶向癌细胞的T细胞，其数量足以显着降低体内肿瘤大小或癌细胞数量。为了克服这个限制，本文提供的纳米颗粒涂覆有呈现肿瘤特异性抗原和共刺激分子的MHC I类和/或II类分子，以及它们将抗原特异性抗致瘤性T细胞扩增至目前免疫治疗未达到的水平技术这些抗原特异性抗致瘤性T细胞包括细胞毒性T细胞，效应T细胞，记忆T细胞和辅助T细胞，其是启动和维持针对转移性或非转移性癌，癌前或非转移性癌症的实质性免疫应答所必需的体内肿瘤细胞。本发明描述了靶向作为淋巴瘤，迁移性转移细胞和实体瘤中循环细胞的癌性或癌前细胞的系统方法。

5. 发明授权

US5972604A DNA sequence-based HLA typing method 失效
标题翻译：基于DNA序列的HLA分型方法
公开(公告)号：US5972604A
公开(公告)日：1999-10-26
申请号：US703136
申请日：1996-08-23
申请人： Pedro Santamaria , Michael Thomas Boyce-Jacino , Jose Joaquim Barbosa , Stephen Saul Rich , Anthony James Faras
发明人： Pedro Santamaria , Michael Thomas Boyce-Jacino , Jose Joaquim Barbosa , Stephen Saul Rich , Anthony James Faras
IPC分类号： C12Q1/68 , C12P19/34 , C07H19/00 , C07H21/04 , C07K1/00
CPC分类号： C12Q1/6881 , C12Q1/6827 , C12Q1/6869 , C12Q2600/156
摘要： The present invention provides a process for determining genotypes in highly polymorphic systems by polymerase chain reaction amplification of CDNA or genomic DNA and direct sequencing polymerase chain reaction products using oligonucleotide primers. More specifically, Class II and Class I HLA genotypes can be unambiguously determined in any subject in 16-24 hours by direct sequencing of DRB, DQB, DQA, DPB, DPA, HLA-A, HLA-B and HLA-C- transcripts enzymatically amplified using a limited number of non-allele-specific oligonucleotides. Total cellular RNA from peripheral blood mononuclear cells is reverse transcribed using antisense primers, specific for different locus (DQB, DQA, DPA or DPB) or group of loci (DRB1-5, or HLA-A and HLA-B and HLA-C). The synthesized cDNA molecules are then enzymatically amplified using different combinations of oligonucleotides for each locus and directly sequenced with Taq polymerase using an internal oligonucleotide. The sequenced genes are then analyzed.
摘要翻译：本发明提供了使用寡核苷酸引物通过聚合酶链反应扩增CDNA或基因组DNA和直接测序聚合酶链反应产物来确定高度多态性系统中的基因型的方法。更具体地，可以在任何受试者16-24小时内通过直接测序DRB，DQB，DQA，DPB，DPA，HLA-A，HLA-B和HLA-C转录物来酶解II类和I类HLA基因型使用有限数量的非等位基因特异性寡核苷酸扩增。来自外周血单核细胞的总细胞RNA使用对不同基因座（DQB，DQA，DPA或DPB）或基因座组（DRB1-5或HLA-A和HLA-B和HLA-C）特异的反义引物进行逆转录，。然后使用每个位点的不同寡核苷酸组合对合成的cDNA分子进行酶扩增，并使用内部寡核苷酸用Taq聚合酶直接测序。然后分析测序的基因。

6. 发明授权

US5629149A DNA sequence-based HLA typing method 失效
标题翻译：基于DNA序列的HLA分型方法
公开(公告)号：US5629149A
公开(公告)日：1997-05-13
申请号：US106802
申请日：1993-08-16
申请人： Pedro Santamaria , Michael T. Boyce-Jacino , Jose J. Barbosa , Stephen S. Rich , Anthony J. Faras
发明人： Pedro Santamaria , Michael T. Boyce-Jacino , Jose J. Barbosa , Stephen S. Rich , Anthony J. Faras
IPC分类号： C12Q1/68 , C12N15/11 , C12Q1/48
CPC分类号： C12Q1/6881 , C12Q1/6827 , C12Q1/6869 , C12Q2600/156
摘要： The present invention provides a process for determining genotypes in highly polymorphic systems by polymerase chain reaction amplification of cDNA or genomic DNA and direct sequencing polymerase chain reaction products using oligonucleotide primers. More specifically, Class II and Class I HLA genotypes can be unambiguously determined in any subject in 16-24 hours by direct sequencing of DRB, DQB, DQA, DPB, DPA, HLA-A, HLA-B and HLA-C- transcripts enzymatically amplified using a limited number of non-allele-specific oligonucleotides. Total cellular RNA from peripheral blood mononuclear cells is reverse transcribed using antisense primers, specific for different locus (DQB, DQA, DPA or DPB) or group of loci (DRB1-5, or HLA-A and HLA-B and HLA-C). The synthesized cDNA molecules are then enzymatically amplified using different combinations of oligonucleotides for each locus and directly sequenced with Taq polymerase using an internal oligonucleotide. The sequenced genes are then analyzed.
摘要翻译：本发明提供了通过使用寡核苷酸引物的cDNA或基因组DNA的聚合酶链反应扩增和直接测序聚合酶链反应产物来确定高度多态性系统中的基因型的方法。更具体地，可以在任何受试者16-24小时内通过直接测序DRB，DQB，DQA，DPB，DPA，HLA-A，HLA-B和HLA-C转录物来酶解II类和I类HLA基因型使用有限数量的非等位基因特异性寡核苷酸扩增。来自外周血单核细胞的总细胞RNA使用对不同基因座（DQB，DQA，DPA或DPB）或基因座组（DRB1-5或HLA-A和HLA-B和HLA-C）特异的反义引物进行逆转录，。然后使用每个位点的不同寡核苷酸组合对合成的cDNA分子进行酶扩增，并使用内部寡核苷酸用Taq聚合酶直接测序。然后分析测序的基因。

7. 发明申请

US20170095544A1 NANOPARTICLE COMPOSITIONS FOR SUSTAINED THERAPY 审中-公开
公开(公告)号：US20170095544A1
公开(公告)日：2017-04-06
申请号：US15348959
申请日：2016-11-10
申请人： Pedro Santamaria
发明人： Pedro Santamaria
IPC分类号： A61K39/00
CPC分类号： A61K47/6929 , A61K39/0008 , A61K39/385 , A61K47/545 , A61K47/60 , A61K47/6909 , A61K47/6935 , A61K2039/57 , A61K2039/60 , A61K2039/627
摘要： This disclosure provides compositions and methods for promoting the formation, expansion and recruitment of TR1 cells and/or B cells in an antigen-specific manner and treating diseases and disorders in a subject in need thereof.

8. 发明申请

US20120093934A1 METHODS FOR TREATING AUTOIMMUNE DISEASE USING BIOCOMPATIBLE BIOABSORBABLE NANOSPHERES 审中-公开
标题翻译：使用生物易生物吸收纳米微粒治疗自身免疫疾病的方法
公开(公告)号：US20120093934A1
公开(公告)日：2012-04-19
申请号：US13249105
申请日：2011-09-29
申请人： Pedro Santamaria
发明人： Pedro Santamaria
IPC分类号： A61K9/16 , G01N33/566 , G01N33/567 , A61K39/385 , A61P37/04 , B82Y5/00
CPC分类号： A61K39/0008 , A61K47/62 , A61K47/6923 , A61K47/6929 , A61K47/6937 , G01N33/505 , G01N2800/24
摘要： The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells using biocompatible bioabsorbable nanospheres. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases.
摘要翻译：所述方法包括使用生物相容性生物可吸收纳米球根据T细胞的抗原特异性选择性还原或扩增T细胞。因此，本发明可用于减少或消除识别自身抗原的致病性T细胞，例如β细胞特异性T细胞。因此，本发明可用于预防，治疗或改善自身免疫性疾病如IDDM。此外，本发明可用于扩展期望的T细胞，例如抗致病性T细胞，以预防，治疗和/或改善自身免疫性疾病。

9. 发明申请

US20110059121A1 COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE CONDITIONS 审中-公开
标题翻译：防止和治疗自身免疫条件的组合物和方法
公开(公告)号：US20110059121A1
公开(公告)日：2011-03-10
申请号：US12848055
申请日：2010-07-30
申请人： Pedro Santamaria , Anna Moore
发明人： Pedro Santamaria , Anna Moore
IPC分类号： A61K39/385 , C07K17/00
CPC分类号： A61K39/0008 , A61K9/5094 , A61K39/385 , A61K47/6923 , A61K47/6929 , A61K2039/55555 , A61K2039/572 , A61K2039/60 , A61K2039/605 , A61K2039/6093 , A61K2039/627 , G01N33/54313 , G01N33/564 , G01N33/56972 , G01N2333/70539 , G01N2800/042
摘要： The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases.
摘要翻译：所述方法包括根据T细胞的抗原特异性选择性地还原或扩增T细胞。因此，本发明可用于减少或消除识别自身抗原的致病性T细胞，例如β细胞特异性T细胞。因此，本发明可用于预防，治疗或改善自身免疫性疾病如IDDM。此外，本发明可用于扩展期望的T细胞，例如抗致病性T细胞，以预防，治疗和/或改善自身免疫性疾病。

10. 发明授权

US5578443A DNA sequence-based HLA typing method 失效
标题翻译：基于DNA序列的HLA分型方法
公开(公告)号：US5578443A
公开(公告)日：1996-11-26
申请号：US665960
申请日：1991-03-06
申请人： Pedro Santamaria , Michael T. Boyce-Jacino , Jose J. Barbosa , Stephen S. Rich , Anthony J. Faras
发明人： Pedro Santamaria , Michael T. Boyce-Jacino , Jose J. Barbosa , Stephen S. Rich , Anthony J. Faras
IPC分类号： C12Q1/68 , C12Q1/48 , C12N15/11 , C12P19/34
CPC分类号： C12Q1/6881 , C12Q2600/156 , C12Q2600/172
摘要： The present invention provides a process for determining genotypes in highly polymorphic systems by polymerase chain reaction amplification of cDNA or genomic DNA and direct sequencing polymerase chain reaction products using oligonucleotide primers. More specifically, Class II and Class I HLA genotypes can be unambiguously determined in any subject in 16-24 hours by direct sequencing of DRB, DQB, DQA, DPB, DPA, HLA-A, HLA-B and HLA-C- transcripts enzymatically amplified using a limited number of non-allele-specific oligonucleotides. Total cellular RNA from peripheral blood mononuclear cells is reverse transcribed using antisense primers, specific for different locus (DQB, DQA, DPA or DPB) or group of loci (DRB1-5, or HLA-A and HLA-B and HLA-C). The synthesized cDNA molecules are then enzymatically amplified using different combinations of oligonucleotides for each locus and directly sequenced with Taq polymerase using an internal oligonucleotide. The sequenced genes are then analyzed.
摘要翻译：本发明提供了通过使用寡核苷酸引物的cDNA或基因组DNA的聚合酶链反应扩增和直接测序聚合酶链反应产物来确定高度多态性系统中的基因型的方法。更具体地，可以在任何受试者16-24小时内通过直接测序DRB，DQB，DQA，DPB，DPA，HLA-A，HLA-B和HLA-C转录物来酶解II类和I类HLA基因型使用有限数量的非等位基因特异性寡核苷酸扩增。来自外周血单核细胞的总细胞RNA使用对不同基因座（DQB，DQA，DPA或DPB）或基因座组（DRB1-5或HLA-A和HLA-B和HLA-C）特异的反义引物进行逆转录，。然后使用每个位点的不同寡核苷酸组合对合成的cDNA分子进行酶扩增，并使用内部寡核苷酸用Taq聚合酶直接测序。然后分析测序的基因。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式